Both EACTS and STS have taken measures against bullying, disrespect, and other harmful behavior. Others may follow suit.

The year had a lot to offer, from advanced therapies aimed at Lp(a), GLP-1, and other targets, to support for simpler ...

Medicine is a balancing act, a mosaic of competing priorities. Just this week, I wrapped up a challenging coronary ...

It was a big news year for structural heart disease. For tricuspid regurgitation, two devices were approved in quick ...

New techniques and devices made headway in tough treatment scenarios, and guidelines stressed the need for collaborative care ...

Researchers delved into the two “neutral” studies using Bayesian methods: a clearer picture of angiography’s role has emerged ...

Headlining the year’s developments were studies of catheter ablation and concomitant use of LAAO in patients with AF.

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

TCTMD's Yael Maxwell, Laura McKeown, Michael O'Riordan, Caitlin Cox, and Todd Neale describe their standout stories.

With new data from several studies this year, researchers are chipping away at the question of when to revascularize and how.

Mamas Mamas, Martha Gulati, and Benoy Shah review the most impactful CV research of the year.